Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 6/20 | 0.37 |
| ▸ | CTSS | P25774 | 4/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300527 | 0.94 | CTSL (0.38) | IDO1CTSLCTSSCTSBCTSK | |
| SCHEMBL6300604 | 0.93 | CTSL (0.38) | IDO1CTSLCTSSCTSBCTSK | |
| SCHEMBL6991868 | 0.92 | CTSL (0.39) | IDO1CTSLCTSSCTSBCTSK | |
| SCHEMBL6699086 | 0.90 | KLKB1 (0.43) | CTSLCTSSCTSBCTSKPPARG | |
| SCHEMBL6294311 | 0.88 | PSMB5 (0.40) | CTSLCTSSCTSBCTSKCA2 | |
| SCHEMBL6698937 | 0.87 | TACR2 (0.40) | CTSLCTSSCTSBCTSKKMT2A | |
| SCHEMBL6295728 | 0.87 | CTSL (0.36) | IDO1CTSLCTSSCTSBCTSK | |
| SCHEMBL6698646 | 0.86 | MEN1 (0.39) | CTSLCTSSCTSBCTSKKMT2A | |
| SCHEMBL6701120 | 0.85 | CTSB (0.49) | CTSLCTSSCTSBCTSKCA2 | |
| SCHEMBL6699096 | 0.85 | CTSL (0.45) | IDO1CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | IDO1 1118/4885CTSL 15/4885CTSS 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.